The Metabolic Syndrome and Schizophrenia: Clinical Research Update

February 1, 2007

The Metabolic Syndrome and Schizophrenia: Clinical Research Update

February 2007, Vol. XXIV, No. 2

Death as a result of cardiovascular (CV) complications represents the leading natural cause of excess mortality in patients with schizophrenia.1 While lifestyle variables such as high rates of smoking, poor dietary habits, and inactivity contribute to CV disease, research has also focused on a cluster of abnormalities that define metabolic syndrome (Table 1). Although considerable debate exists about whether a diagnosis of metabolic syndrome confers added CV risk compared with that attributable to the individual criteria, there is little doubt that the syndrome captures a group of individuals at risk for both CV disease and type 2 diabetes mellitus.2

The clinical usefulness of the metabolic syndrome concept is its ability to focus attention on a cluster of abnormalities that in isolation may not attract much clinical interest. Underlying the development of metabolic syndrome (also referred to as syndrome X or the dysmetabolic syndrome) is the finding that compensatory hyperinsulinemia, in certain abdominally obese persons, is associated with dyslipidemia, hypertension, and inflammatory markers.3 Those features distinguish patients with metabolic syndrome from overweight or obese individuals in whom hyperinsulinemia develops in the presence of decreased peripheral insulin sensitivity but without the other dysmetabolic components.

Increased diabetes mellitus prevalence has been noted in patients with schizophrenia in many countries,4 but the greater public health concern is the prevention of diabetes and preservation of b-cell function in patients who are prediabetic.5 For that reason, recent studies of patients with schizophrenia have increasingly focused on the prevalence of prediabetic states such as the metabolic syndrome. Issues in the literature revolve around the prevalence of the syndrome as a whole and that of the individual criteria, how these prevalence data compare with those in matched individuals from the general population, and the role of antipsychotic medications.

The purpose of this article is to review some of the newer findings that probe the link between metabolic syndrome and schizophrenia and to investigate whether compelling data exist to demonstrate medication-independent risk for metabolic disease in patients with schizophrenia. Recent consensus recommendations for monitoring and preventing metabolic dysfunction will be discussed, along with studies outlining comparative therapeutic options for those who meet metabolic syndrome criteria.

Prevalence data, disease, and medication effects
The diagnostic criteria used in many studies are based on those elaborated by the National Cholesterol Education Program (NCEP) in 20016 and subsequently updated by lowering the fasting glucose threshold to 100 mg/dL to match that established by the American Diabetes Association (ADA) for prediabetes7 (Table 1). Although abdominal obesity is considered a core feature of the syndrome, the NCEP definition allowed the diagnosis to be established by meeting any 3 of the 5 criteria, prompting the International Diabetes Federation (IDF) to create a newer definition that mandates abdominal obesity as a necessary criterion, combined with any 2 of the 4 remaining components.

Regardless of the definition, the past 2 years have seen the publication of multiple articles on the prevalence of metabolic syndrome, predominantly using North American or Western European samples, including several large studies that compared prevalences in patients with schizophrenia with those in matched comparison controls from the general population (Table 2). 8-10 Among the recent studies, 2 recruited patients with schizophrenia or schizoaffective disorder on the basis of obesity11,12 and have limited generalizability.

The first large published estimate is from a study of 240 Canadian patients with schizophrenia or schizoaffective disorder (65% male, mean age 43.3 years). The investigators found a prevalence of 42.6% for men and 48.5% for women, using the NCEP criteria8; these rates are 2-fold greater than comparable published estimates in the United States. In their study using a cohort born in 1966 in northern Finland, Saari and colleagues10 found a 4-fold increased risk for NCEP-defined metabolic syndrome in the 31 patients with schizophrenia compared with their 5500 demographically identical peers. The largest non-US data set is an analysis of 430 Belgian patients with schizophrenia that, using NCEP criteria, showed a prevalence of 28.4% for metabolic syndrome (32.3% with the updated NCEP definition and 36.0% using the IDF definition). Again, this prevalence for metabolic syndrome was at least twice as high as that of an age-adjusted community sample in Belgium.13

The most comprehensive and largest comparative analysis of metabolic syndrome prevalence emerged from the baseline sample in the National Institute of Mental Health–funded Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.9 The data-dense findings from multiple analyses of metabolic syndrome and prevalence criteria on the basis of age, sex, and race/ethnicity were compared with a demographically matched sample from the Third National Health and Nutrition Examination Survey (NHANES III).

There were several important findings of CATIE worth highlighting, including the fact that increased metabolic syndrome prevalence (compared with NHANES III) was seen across nearly all individual metabolic syndrome criteria for men and women (Table 3). The discrepancy in prevalence was found in patients with schizophrenia as young as those aged 20 through 30 and was always greatest for women. A sex difference in metabolic syndrome prevalence was found in the general population (approximately 25% greater in women),14 but this difference was magnified to 42% within the schizophrenia population. Adding further clinical concern were the low rates of treatment for metabolic syndrome components evaluated as part of CATIE.15

Another finding that emerged from the CATIE baseline analysis was the association between metabolic syndrome and poor perceived health.16 After adjustment for demographic variables, those with metabolic syndrome rated themselves significantly lower on physical health and scored higher on somatic preoccupation (P = .03). This echoes earlier data from the Patient Outcomes Research Team study that documented an association between poor physical and mental health in patients with schizophrenia.17

What the various data from treated patients who have schizophrenia cannot answer is the extent to which the disease itself presents a risk for metabolic dysfunction independent of antipsychotic exposure. Some small early studies from a group in Ireland seemed to suggest that increased visceral adiposity and glycemic abnormalities could be found in untreated and neuroleptic-naive patients with schizophrenia,18,19 but these findings have not been replicated. A larger and more rigorous study from China found no pretreatment differences in visceral fat or other metabolic parameters between patients with schizophrenia and matched controls,20 but marked differences emerged immediately after antipsychotic exposure.

Similarly, a Spanish study that compared 50 neuroleptic-naive subjects with schizophrenia with 50 nonadherent patients with schizophrenia and 50 control subjects found no differences in metabolic measures between the neuroleptic-naive cohort and the control subjects, arguing against a unique predisposition toward glycemic dysfunction in patients with schizophrenia.21 The nonadherent patients with schizophrenia, antipsychotic-free at the time of analysis, showed significantly increased markers of insulin resistance compared with patients who were antipsychotic-naive and the control cohort, indicating the effects of earlier treatment as an important causative factor in the high prevalence of metabolic dysfunction seen in treated cohorts with schizophrenia.

While the debate over disease effects awaits more studies of neuroleptic-naive patients with schizophrenia, the relative contribution of various antipsychotics has become firmly established. Following early expert opinion that olanzapine and clozapine are the antipsychotic agents with the highest risk for metabolic dysfunction,22 the large CATIE schizophrenia trial (n = 1460) provided sound confirmation of this conclusion while noting that ziprasidone appears to be metabolically neutral.23-25 Aripiprazole was not included in the first 2 phases of CATIE, but data from long-term prospective studies (26 and 52 weeks) also indicate a benign metabolic profile comparable to that for ziprasidone.26

Obesity increases risk for metabolic dysfunction, but reports of type 2 diabetes mellitus and ketoacidosis occurring in patients with schizophrenia without marked weight gain raised the issue of weight-independent drug effects on glucose/insulin homeostasis.27 Aside from clinical data provided by these case reports, compelling biologic findings have emerged from animal28 and human studies,29 which indicate that olanzapine not only increases weight but appears to preferentially induce increases in visceral adiposity.

Moreover, exposure to single doses of clozapine and olanzapine is associated with decreased peripheral insulin sensitivity in a dose-dependent manner in laboratory animals.30 Insulin normally acts to suppress hepatic gluconeogenesis, but clozapine and olanzapine appear to interfere with this process immediately after exposure, resulting in abnormal hepatic glucose output from the liver. This presents the most compelling argument for weight-independent effects of these medications on metabolic function, although confirmation of this effect in human studies with larger samples is required.

Monitoring and treatment
In response to the obvious public health impact of the high prevalence of metabolic syndrome, several expert and consensus panels have convened in the United States,22,31 Canada, and Belgium32-34 to support aggressive monitoring of metabolic parameters in all patients exposed to antipsychotics. At the minimum, those prescribing antipsychotics should obtain baseline and annual measures of all variables that encompass metabolic syndrome criteria-including waist circumference-with more frequent monitoring suggested for weight (typically at each visit), lipids, and glucose related to aggregate risk from the antipsychotic agent itself (Table 4).

In addition, patient variables including age, personal or family history, and ethnicity should be recorded. The ADA consensus panel did not provide clear guidelines for treatment of all antipsychotic-related metabolic problems, but the parameters that define the metabolic syndrome provide useful markers for determining when to intervene. The sole exception is weight gain, for which the ADA consensus panel recommended intervention when the patient experiences a 5% weight gain,22 since most individuals have difficulty in losing more than 5% on their own.

Once abnormalities have been identified, both the ADA consensus panel22 and NCEP suggest a trial of lifestyle modification for up to 3 months.6 The clinical difficulty rests in the fact that these programs are not widely available to patients with schizophrenia, and even those targeted for weight reduction in this population often fail to achieve clinical goals.35Nonetheless, when available they should be offered, but the interventions must be reassessed for effectiveness after 3 months. If no progress toward metabolic goals has occurred, other strategies must be pursued, including pharmacotherapy for hyperlipidemia, hypertension, or mild type 2 diabetes or switching from metabolically offending antipsychotic medications.

The conundrum facing many practitioners is whether to treat metabolic problems as they arise, or attempt to switch patients from metabolically offending medications and thus obviate the need for referral and additional medications. For patients with refractory schizophrenia who are being treated with clozapine, the absence of other viable medication choices precludes switching, but extensive data from industry switch studies,12,36,37 other switch data,38 and the CATIE schizophrenia trial23 demonstrate that many patients can be switched to metabolically more benign antipsychotics without loss of effectiveness. A reanalysis of the CATIE phase 1 data showed that the patients who were randomized to the same antipsychotic medication taken at study entry (in essence, nonswitchers) continued to take their medication longer than those who were switched to a new medication, arguing for attempts at behavioral or other management of metabolic problems as the first step before medication changes.39

For those patients for whom switching is not feasible or initially preferred, establishment of relationships with primary care providers is paramount to ensure that the patient receives appropriate follow-up and treatment. Further research will help clarify the risks and benefits of switching for metabolic purposes and elucidate the biologic mechanisms for drug-related metabolic effects (and disease-related effects if they exist), but minimization of CV risk remains a major clinical goal during antipsychotic therapy of schizophrenia.

Dr Meyer is attending psychiatrist at the Veterans Affairs San Diego Healthcare System in La Jolla, Calif, and assistant professor of psychiatry at the University of California, San Diego School of Medicine. Dr Meyer discloses that he has received a research grant from Bristol-Myers Squibb and Pfizer; he is on the Speakers Bureau at Bristol-Myers Squibb, Pfizer, and Janssen; and he is a consultant for Bristol-Myers Squibb, Pfizer, Janssen, Wyeth, Sanofi, AstraZeneca, and Abbott Laboratories.

Drugs Mentioned in This Article
Aripiprazole (Abilify)
Clozapine (Clozaril)
Olanzapine (Zyprexa)
Topiramate (Topamax)
Ziprasidone (Geodon)

References1. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res. 2000;45:21-28.
2. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165:2644-2650.
3. Reaven GM. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals. Endocrinol Metab Clin North Am. 2005;34:49-62.
4. Bushe C, Holt R. Prevalence of diabetes and glucose intolerance in patients with schizophrenia. Br J Psychiatry. 2004;184(suppl 47):67-71.
5. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
6. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486-2497.
7. Grundy SM, Brewer B, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.
8. Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49:753-760.
9. McEvoy JP, Meyer JM, Nasrallah HA, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.
10. Saari KM, Lindeman SM, Viilo KM, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 birth cohort study. J Clin Psychiatry. 2005;66:559-563.
11. Basu R, Brar JS, Chengappa KN, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord. 2004;6: 314-318.
12. Meyer JM, Pandina G, Bossie CA, et al. Impact of an open-label switch from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder. Clin Ther. 2005;27:1930-1941.
13. De Hert MA, van Winkel R, van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83:87-93.
14. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care. 2004;27:2444-2449.
15. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE Schizophrenia Trial sample at baseline. Schizophr Res. 2006;86:15-22.
16. Meyer JM, Nasrallah HA, McEvoy JP, et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res. 2005;80:9-18.
17. Dixon L, Postrado L, Delahanty J, et al. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis. 1999;187: 496-502.
18. Thakore JH, Mann JN, Vlahos I, et al. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. J Int Assoc Study Obesity. 2002;26: 137-141.
19. Ryan MC, Flanagan S, Kinsella U, et al. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci. 2004;74:1999-2008.
20. Zhang ZJ, Yao ZJ, Liu W, et al. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry. 2004;184:58-62.
21. Arranz B, Rosel P, Ramirez N, et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry. 2004;65:1335-1342.
22. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65:267-272.
23. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
24. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600-610.
25. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163:611-622.
26. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-95.
27. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002;14:59-64.
28. Ader M, Kim SP, Catalano KJ, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes. 2005; 54:862-871.
29. Graham KA, Perkins DO, Edwards LJ, et al. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry. 2005;162:118-123.
30. Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2006 Oct 11; [Epub ahead of print].
31. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161:1334-1349.
32. De Nayer A, De Hert M, Scheen A, et al. Conference report: Belgian consensus on metabolic problems associated with second-generation antipsychotics. Int J Psychiatry Clin Pract. 2005;9:130-137.
33. Poulin MJ, Cortese L, Williams R, et al. Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring. Can J Psychiatry. 2005;50:555-562.
34. De Hert M, van Eyck D, De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol. 2006;21(suppl 2):S11-S15.
35. Loh C, Meyer JM, Leckband SG. A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry. 2006;18:23-31.
36. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology. 2003;166:391-399.
37. Weiden PJ, Loebel A, Yang R, Lebovitz H. Course of weight and metabolic benefits 1 year after switching to ziprasidone. Presented at: American Psychiatric Association Annual Meeting; May 5, 2004; New York. Abstract.
38. Gupta S, Masand PS, Virk S, et al. Weight decline in patients switching from olanzapine to quetiapine. Schizophr Res. 2004;70:57-62.
39. Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163:2090-2095.
40. International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome, Brussels. Available at: Accessed on December 27, 2006.
41. Meyer JM, Loh C, Leckband SG, et al. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract. 2006;12:5-10.
42. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry. 2006;67:575-583.
43. Hagg S, Lindblow Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol. 2006;21:93-98.

Evidence-Based References

  • Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2006 Oct 11; [Epub ahead of print].
  • McEvoy JP, Meyer JM, Nasrallah HA, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.